ATE421340T1 - Verfahren zur quantitativen und selektiven funktionalisierung von immunoglobulin-fab- fragmenten, deren konjugate und deren zusammensetzungen - Google Patents
Verfahren zur quantitativen und selektiven funktionalisierung von immunoglobulin-fab- fragmenten, deren konjugate und deren zusammensetzungenInfo
- Publication number
- ATE421340T1 ATE421340T1 AT03779875T AT03779875T ATE421340T1 AT E421340 T1 ATE421340 T1 AT E421340T1 AT 03779875 T AT03779875 T AT 03779875T AT 03779875 T AT03779875 T AT 03779875T AT E421340 T1 ATE421340 T1 AT E421340T1
- Authority
- AT
- Austria
- Prior art keywords
- conjugates
- fab fragment
- quantitative
- compositions
- fab fragments
- Prior art date
Links
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title abstract 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title abstract 5
- 238000007306 functionalization reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000021615 conjugation Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02025315A EP1419786A1 (de) | 2002-11-13 | 2002-11-13 | Verfahren zur quantitativen und selektiven Funktionalisierung von Immunoglobulin-Fab-Fragmenten, deren Konjugate und deren Zusammensetzungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE421340T1 true ATE421340T1 (de) | 2009-02-15 |
Family
ID=32116242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03779875T ATE421340T1 (de) | 2002-11-13 | 2003-11-10 | Verfahren zur quantitativen und selektiven funktionalisierung von immunoglobulin-fab- fragmenten, deren konjugate und deren zusammensetzungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060120959A1 (de) |
| EP (3) | EP1419786A1 (de) |
| JP (2) | JP4801352B2 (de) |
| CN (1) | CN1711108B (de) |
| AT (1) | ATE421340T1 (de) |
| AU (1) | AU2003288022B2 (de) |
| CA (1) | CA2503647C (de) |
| DE (1) | DE60325996D1 (de) |
| WO (1) | WO2004043492A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US7837980B2 (en) * | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| WO2007128873A1 (en) * | 2006-05-05 | 2007-11-15 | Wallac Oy | A method for the preparation of maleimido derivatives of biomolecule labeling reactants and conjugates derived thereof |
| WO2009012288A2 (en) * | 2007-07-17 | 2009-01-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging |
| WO2009058203A1 (en) * | 2007-10-29 | 2009-05-07 | Albert Einstein College Of Medicine Of Yeshiva University | Radiolabeled monoclonal antibodies, methods of preparation using tcep, and uses thereof |
| MX2011005672A (es) * | 2008-11-28 | 2011-06-20 | Abbott Lab | Composiciones de anticuerpo estables y metodos para estabilizar a las mismas. |
| JP2016531915A (ja) | 2013-08-28 | 2016-10-13 | ステムセントリックス， インコーポレイテッド | 部位特異的抗体コンジュゲーション方法および組成物 |
| AU2014346792A1 (en) | 2013-11-06 | 2016-06-02 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
| KR20160097336A (ko) | 2013-12-12 | 2016-08-17 | 스템센트알엑스 인코포레이티드 | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 |
| EP3107576A4 (de) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3-antikörper und arzneimittelkonjugate zur verwendung in melanomen |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| KR20230136699A (ko) | 2016-06-06 | 2023-09-26 | 노쓰웨스턴유니버시티 | 융합 단백질 작제물 |
| CN107764992B (zh) * | 2017-10-16 | 2018-10-12 | 南京诺唯赞医疗科技有限公司 | 一种微球与抗体的定向偶联方法及应用 |
| US20200408688A1 (en) * | 2018-03-23 | 2020-12-31 | Konica Minolta, Inc. | Labeled antibody dispersion liquid and kit for spfs |
| CN111505293B (zh) * | 2020-04-03 | 2022-11-18 | 北京望尔生物技术有限公司 | 一种检测杂色曲霉素的试纸条及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5616417A (en) | 1979-07-19 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| CA1260828A (en) | 1983-07-04 | 1989-09-26 | Masakazu Iwai | Therapeutic and prophylactic agent for gastrointestinal ulcers |
| US5082930A (en) | 1986-05-29 | 1992-01-21 | Mallinckrodt Medical, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
| DE3701665A1 (de) | 1987-01-19 | 1988-07-28 | Schering Ag | Polymer-komplexe, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel |
| DE3807904A1 (de) | 1988-03-10 | 1989-09-21 | Behringwerke Ag | Magnetische protein-konjugate, verfahren zu ihrer herstellung und ihre verwendung |
| US5612016A (en) | 1988-04-01 | 1997-03-18 | Immunomedics, Inc. | Conjugates of antibodies and bifunctional ligands |
| US5541297A (en) * | 1988-04-01 | 1996-07-30 | Immunomedics, Inc. | Therapeutic conjugates of toxins and drugs |
| US5061641A (en) * | 1988-04-01 | 1991-10-29 | Immunomedics, Inc. | Method for radiolabeling proteins |
| US5274119A (en) * | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| CA1339415C (en) | 1989-08-24 | 1997-09-02 | Milton David Goldenberg | Detection and treatment of infections with immunoconjugates |
| CA1340250C (en) * | 1989-09-18 | 1998-12-15 | Hans J. Hansen | Method for rapidly radiolabeling monovalent antibody fragments with technetium |
| WO1991004755A1 (en) * | 1989-09-29 | 1991-04-18 | Neorx Corporation | Methods for reducing non-target retention of immunoconjugates and metabolites thereof |
| US5494655A (en) * | 1990-03-09 | 1996-02-27 | The Regents Of The University Of California | Methods for detecting blood perfusion variations by magnetic resonance imaging |
| IL97459A0 (en) | 1990-03-09 | 1992-06-21 | Hybritech Inc | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
-
2002
- 2002-11-13 EP EP02025315A patent/EP1419786A1/de not_active Withdrawn
-
2003
- 2003-11-10 AU AU2003288022A patent/AU2003288022B2/en not_active Ceased
- 2003-11-10 CA CA2503647A patent/CA2503647C/en not_active Expired - Fee Related
- 2003-11-10 JP JP2004550961A patent/JP4801352B2/ja not_active Expired - Fee Related
- 2003-11-10 AT AT03779875T patent/ATE421340T1/de not_active IP Right Cessation
- 2003-11-10 DE DE60325996T patent/DE60325996D1/de not_active Expired - Lifetime
- 2003-11-10 US US10/532,446 patent/US20060120959A1/en not_active Abandoned
- 2003-11-10 CN CN2003801032086A patent/CN1711108B/zh not_active Expired - Fee Related
- 2003-11-10 EP EP07123000A patent/EP1900379A2/de not_active Withdrawn
- 2003-11-10 EP EP03779875A patent/EP1560600B1/de not_active Expired - Lifetime
- 2003-11-10 WO PCT/EP2003/012514 patent/WO2004043492A1/en not_active Ceased
-
2011
- 2011-04-14 JP JP2011089945A patent/JP2011148820A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004043492A1 (en) | 2004-05-27 |
| EP1900379A2 (de) | 2008-03-19 |
| CA2503647A1 (en) | 2004-05-27 |
| EP1560600B1 (de) | 2009-01-21 |
| CN1711108B (zh) | 2010-10-06 |
| AU2003288022B2 (en) | 2009-04-30 |
| US20060120959A1 (en) | 2006-06-08 |
| JP2006508954A (ja) | 2006-03-16 |
| DE60325996D1 (de) | 2009-03-12 |
| CN1711108A (zh) | 2005-12-21 |
| JP4801352B2 (ja) | 2011-10-26 |
| AU2003288022A1 (en) | 2004-06-03 |
| JP2011148820A (ja) | 2011-08-04 |
| CA2503647C (en) | 2012-07-03 |
| EP1419786A1 (de) | 2004-05-19 |
| EP1560600A1 (de) | 2005-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60325996D1 (de) | Verfahren zur quantitativen und selektiven funktionalisierung von immunoglobulin-fab-fragmenten, deren konjugate und deren zusammensetzungen | |
| AU563356B2 (en) | Conjugate of enzyme and antibody | |
| MXPA03009408A (es) | Factor de crecimiento endotelial vascular 2. | |
| DK1265928T3 (da) | RSV-neutraliserende antistoffer med ultra høj affinitet | |
| EP1064308A4 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
| BR0212968A (pt) | Composição farmacêutica, composto, e, método para tratar ou prevenir condições mediadas pelo ccr2, mcp-1 ou pela interação destes | |
| ATE548386T1 (de) | Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften | |
| CY1109817T1 (el) | Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου | |
| PE20020871A1 (es) | Moleculas de enlace terapeuticas | |
| CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
| ID27299A (id) | Senyawa-senyawa arsen sulfida dan turunan-turunannya untuk mengobati maglinansis | |
| DE59010418D1 (de) | Monoklonale Antikörper (MAK) gegen tumorassoziierte Antigene, ihre Herstellung und Verwendung | |
| ATE140917T1 (de) | Chelatbildende verbindungen, die eine ortho- bindende gruppe besitzen und ihre komplexe | |
| DK1545609T3 (da) | Antistoffer rettet mod oxideret apolipoprotein B | |
| DE3773077D1 (de) | Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| DE69331479D1 (de) | Polyethylenglycol-Hirudin-Konjugate, deren Verfahren zur Herstellung und Verwendung für die Heilung von Thrombosen | |
| DE59310280D1 (de) | Verfahren zur Herstellung von Konjugaten aus einem spezifischen Bindungspartner und einem kohlenhydrathaltigen Protein | |
| NO900186L (no) | Kondenserte benzazepiner. | |
| DK1100829T3 (da) | Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme | |
| DE69900283D1 (de) | Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment | |
| SE7809402L (sv) | Treatment of reinforcing silica | |
| DK0528527T3 (da) | Konjugater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |